News|Articles|August 2, 2023

NIH Names Jeanne Marrazzo, MD, to Lead National Institute of Allergy and Infectious Diseases

Author(s)Alicia Bigica

Marrazzo is currently the director of the Division of Infectious Diseases at the University of Alabama at Birmingham, and will assume her role at the NIAID in the fall.

Nearly 8 months after Anthony Fauci, MD, stepped down, the National Institutes of Health (NIH) has named Jeanne Marrazzo, MD, as director of the National Institute of Allergy and Infectious Diseases (NIAID). Marrazzo, currently director of the Division of Infectious Diseases at the University of Alabama at Birmingham, will assume her role at the NIAID in the fall.

In a position that skyrocketed to the front of the public's eye during the COVID-19 pandemic, Marrazzo will be responsible for overseeing the NIAID's $6.3 billion budget, the NIH's second largest after the National Cancer Institute. The budget supports research that contributes to the understanding, diagnosis, and treatment of infectious, immunologic, and allergic diseases, including research that occurrs at universities and research organizations in the US and at NIAID's 21 laboratories, which include the Vaccine Research Center and the Rocky Mountains Laboratories.

Professionally, Marrazzo's work has focused on the human microbiome, specifically in relation to female reproductive health and hormonal contraception, HIV prevention, as well as management of bacterial vaginosis, sexually transmitted diseases in people with HIV, and antibiotic-resistant gonorrhea. A prolofic principal investigator, peer-reviewer, and advisory committee member, Marrazzo has mentored extensively in the field and is the recipient of the American Sexually Transmitted Diseases Association’s Distinguished Career Award.

“Dr. Marrazzo brings a wealth of leadership experience from leading international clinical trials and translational research, managing a complex organizational budget that includes research funding and mentoring trainees in all stages of professional development,” said acting director of the NIH Lawrence Tabak, DDS, PhD, in a statement.

Marrazzo will replace acting NIAID director Hugh Auchincloss, Jr., MD, who assumed the role after Fauci stepped down from the post after serving as NIAID director for nearly 40 years.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.